Microencapsulation of protein into biodegradable matrix: a smart solution cross-linking technique

Sustained-release albumin microspheres (MSs) can be obtained by chemically cross-linking albumin. However, a significant challenge is preventing the cross-linking of the active pharmaceutical (protein or small molecule) ingredient (API) with the MS matrix. To prevent cross-linking of the API with th...

Full description

Saved in:
Bibliographic Details
Published inJournal of microencapsulation Vol. 30; no. 3; pp. 274 - 282
Main Authors Bejugam, Naveen K., Gayakwad, Sanjay G., Uddin, Akm N., D'souza, Martin J.
Format Journal Article
LanguageEnglish
Published Colchester Informa UK, Ltd 01.01.2013
Taylor & Francis
Informa
Subjects
albumin
Biocompatible Materials
Biological and medical sciences
cross-linking
Drug Compounding
General pharmacology
glutaraldehyde
lysozyme
Medical sciences
microencapsulation
microspheres
Muramidase - metabolism
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Spectroscopy, Fourier Transform Infrared
Microsphere
Pharmaceutical technology
Enzyme
Biodegradability
microspheres
Albumin
Crosslinking
glutaraldehyde
Glutaral
Protein
Glycosylases
cross-linking
Glycosidases
Antiseptic
Hydrolases
Microparticle
Antiviral
Microencapsulation
Disinfecting agent
Lysozyme
Solution
Matrix system
Online AccessGet full text

Cover

More Information
Summary:Sustained-release albumin microspheres (MSs) can be obtained by chemically cross-linking albumin. However, a significant challenge is preventing the cross-linking of the active pharmaceutical (protein or small molecule) ingredient (API) with the MS matrix. To prevent cross-linking of the API with the albumin matrix, a smart "solution cross-linking-microencapsulation" method was developed which involves cross-linking albumin solution with glutaraldehyde first, neutralizing any excess glutaraldehyde with sodium bisulphite, followed by the addition of API and finally spray drying. Using lysozyme as model API, MS formulations FL1 and FL2 were prepared and characterized. Physicochemical characterization using FT-IR and bioactivity evaluation indicate that microencapsulated API did not undergo any significant change in its native structure and the bioactivity was preserved during the formulation processing. Preliminary immunogenicity potential of the cross-linked albumin matrix determined by in vivo studies did not show any significant increase in antigen-specific serum-IgG levels, implying safety and biocompatibility of the cross-linked albumin matrix.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0265-2048
1464-5246
DOI:10.3109/02652048.2012.720724